Serum S100B levels were significantly reduced in the control group compared to ADHD patients at T0 [control group: 0.0938 (0.035) μg/L vs. ADHD group: 0.2204 (0.089) μg/L at T0 (p < 0.001)] (Figure 3). Here, S100B is linked to attention deficit-hyperactivity disorder.